RESUMEN
Heart failure (HF) is a huge global public health task due to morbidity, mortality, disturbed quality of life, and major economic burden. It is an area of active research and newer treatment strategies are evolving. Recently angiotensin receptor-neprilysin inhibitor (ARNI), a class of drugs (the first agent in this class, Sacubitril–Valsartan), reduces cardiovascular mortality and morbidity in chronic HF patients with reduced left ventricular ejection fraction (LVEF). Positive therapeutic effects have led to a decrease in cardiovascular mortality and HF hospitalizations (HFH), with a favorable safety profile, and have been documented in several clinical studies with an unquestionable survival benefit with ARNI, Sacubitril–Valsartan. This consensus statement of the Indian group of experts in cardiology, nephrology, and diabetes provides a comprehensive review of the power and promise of ARNI in HF management and an evidence-based appraisal of the use of ARNI as an essential treatment strategy for HF patients in clinical practice. Consensus in this review favors an early utility of Sacubitril–Valsartan in patients with HF with reduced EF (HFrEF), regardless of the previous therapy being given. A lower rate of hospitalizations for HF with Sacubitril–Valsartan in HF patients with preserved EF who are phenotypically heterogeneous suggests possible benefits of ARNI in patients having 40–50% of LVEF, frequent subtle systolic dysfunction, and higher hospitalization risk.
RESUMEN
For new antifungal antibiotics from actinomycetes, a strain of Streptomyces GS 1322 was isolated from a sample of garden soil. The strain was found to possess antagonistic activity against four fungi i.e., Candida albicans, Aspergillus niger, Microsporum gypseum and Trichophyton sp. The strain was identified as Streptomyces sampsonii and the antifungal compound produced by it was found to be the heptaene group of polyene antibiotics.
Asunto(s)
Antibiosis , Antifúngicos/biosíntesis , Aspergillus niger/crecimiento & desarrollo , Candida albicans/crecimiento & desarrollo , ADN Ribosómico/genética , Microsporum/crecimiento & desarrollo , ARN Ribosómico 16S/genética , Microbiología del Suelo , Espectrofotometría Ultravioleta , Streptomyces/química , Trichophyton/crecimiento & desarrolloRESUMEN
A strain of Streptomyces purpeofuscus CM 1261 isolated from a sample of compost collected locally was found to possess strong antagonistic activity against 4 human pathogenic fungi i.e., Candida albicans, Aspergillus niger, Microsporum gypseum and Trichophyton sp. The active antifungal compound produced by it was found to be a heptaene group of polyene antifungal antibiotic.
Asunto(s)
Antifúngicos/aislamiento & purificación , Aspergillus niger/efectos de los fármacos , Candida albicans/efectos de los fármacos , Pruebas de Sensibilidad Microbiana , Microsporum/efectos de los fármacos , Hongos Mitospóricos/efectos de los fármacos , Polienos , Streptomyces/metabolismo , Trichophyton/efectos de los fármacosRESUMEN
Seventeen strains of actinomycetes antagonistic to yeast and moulds have been tested for their ability to produce amylase, lipase, gelatinase and caseinase using solid media containing starch, Tween-20, gelatin and skimmed milk, respectively, Enzyme producing potential of test strains is expressed in ternis of relative enzyme activity (REA). Actinomycetes strain Streptomyces somaliensis GS 1242 and Streptomyces sampsonii GS 1322 showed higher amylase production (REA 6.5) while maximum lipase activity was noted in Streptomyces strain SAP 1089 (REA 7.0). Gelatinase activity was noted higher is S. sampsonii GS 1322 (REA 9.6) and S. somaliensis GS 1242 (REA 8.8). Enzyme producing potential of these strains has been discussed in terms of their industrial significance.